KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

Core Insights - KALA BIO, Inc. has completed patient enrollment in the CHASE Phase 2b clinical trial for KPI-012, aimed at treating persistent corneal epithelial defect (PCED) [1][3] - The trial is a multicenter, randomized, double-masked, vehicle-controlled study evaluating the safety and efficacy of two doses of KPI-012 [2] - KALA expects to report topline data by the end of Q3 2025, with the potential for the CHASE trial to support a Biologics License Application (BLA) submission contingent on positive results [1][3] Company Overview - KALA BIO is a clinical-stage biopharmaceutical company focused on innovative therapies for rare and severe eye diseases [4] - The lead product candidate, KPI-012, is based on a proprietary mesenchymal stem cell secretome (MSC-S) platform and has received Orphan Drug and Fast Track designations from the FDA for PCED [4] - The company is also exploring KPI-012 for other indications, including Limbal Stem Cell Deficiency and retinal degenerative diseases [4]